Featured Research

from universities, journals, and other organizations

Liver Transplant Recipients With Hepatitis B May Need Lifelong Antiviral Treatment

Date:
February 26, 2009
Source:
Wiley-Blackwell
Summary:
Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back. A new study shows that they lack cellular immunity against the disease, making recurrence likely if antiviral treatment is withdrawn.

Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back. A new study shows that they lack cellular immunity against the disease, making recurrence likely if antiviral treatment is withdrawn.

Chronic hepatitis B (HBV) is a common cause of advanced liver disease and liver cancer. Liver transplantation is the most effective treatment, however, without ongoing antiviral therapy, HBV recurs in 80 percent of recipients. While the patient’s immune system plays a critical role in both viral clearance and liver injury, the role of HBV-specific cellular immunity in liver transplant patients has been unclear.

Researchers, led by Chung Mau Lo, of The University of Hong Kong, set out to understand this immunity in patients with HBV who received a liver transplant. They examined HBV-specific CD4 T-cell immune response in 52 HBV patients who’d undergone liver transplantation. Forty of these patients had experienced HBV recurrence and 12 had not. They compared data from 63 people with HBV who had not undergone transplantation. Forty such patients had chronic HBV and 23 had self-limited infection.

Researchers introduced HBV-encoded antigens to blood samples from each patient. They then determined T-cell proliferation and interferon-γ production in vitro. They found that cellular immunity in transplant recipients with recurrence was not significantly different from that of chronically infected individuals with elevated aminotransferases. However, transplant patients without recurrence had lower or undetectable CD4 T-cell response.

“Our results provide strong evidence to support the concept that the CD4 T cell-mediated immune response is an antigen-driven process,” the authors report.

An accompanying editorial by Anne Marie Roque-Afonso of Hopital Paul Brousse in France suggests that the study points to the need for indefinite antiviral therapy in liver transplant recipients with HBV, due to their lack of anti-HBV immunity.

“Immunosuppression following liver transplantation for HBV-related disease presents the maximal risk of viral reactivation and mandates life-long prophylaxis,” she concludes.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal References:

  1. Luo et al. Hepatitis B virus-specific CD4 T cell immunity after liver transplantation for chronic hepatitis B. Liver Transplantation, 2009; 15 (3): 292 DOI: 10.1002/lt.21674
  2. Roque-Afonso, Anne-Marie. Hepatitis B Virus Cellular Immunity After Liver Transplantation: A Role in Preventing HBV Recurrence? Liver Transplantation, March 2009

Cite This Page:

Wiley-Blackwell. "Liver Transplant Recipients With Hepatitis B May Need Lifelong Antiviral Treatment." ScienceDaily. ScienceDaily, 26 February 2009. <www.sciencedaily.com/releases/2009/02/090226131705.htm>.
Wiley-Blackwell. (2009, February 26). Liver Transplant Recipients With Hepatitis B May Need Lifelong Antiviral Treatment. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2009/02/090226131705.htm
Wiley-Blackwell. "Liver Transplant Recipients With Hepatitis B May Need Lifelong Antiviral Treatment." ScienceDaily. www.sciencedaily.com/releases/2009/02/090226131705.htm (accessed April 17, 2014).

Share This



More Health & Medicine News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins